Noscapine-¹³C,d₃ 

Noscapine-13C,d3 is a deuterated labeled Noscapine^[1]. Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier^{[2][3][4][5][6]}.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].
Noscapine (0-1000 μM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC₅₀ of 250 μM at 72 hours^[2].
Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation^[2].
Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Noscapine (300?mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

417.43

C₂₁¹³CH₂₀D₃NO₇

1217680-57-3

128-62-1

COC1=C(OCO2)C2=CC3=C1[C@@]([C@]4([H])C5=CC=C(OC)C(OC)=C5C(O4)=O)([H])N(CC3)[13C]([2H])([2H])[2H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201.  [Content Brief]

  [3]. Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043.  [Content Brief]

  [4]. Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66.  [Content Brief]

  [5]. S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55.  [Content Brief]

  [6]. Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188.  [Content Brief]